Formycon's Ustekinumab Biosimilar FYB202 Shows Comparable Efficacy to Stelara® in Clinical Studies
核心洞察
Formycon's FYB202 demonstrated analytical and functional comparability to reference ustekinumab (Stelara®) through comprehensive laboratory testing and clinical studies.
Phase III efficacy study involving 392 psoriasis patients and Phase I pharmacokinetics study with 491 healthy volunteers confirmed therapeutic equivalence of FYB202.
The biosimilar received regulatory approvals from FDA, EMA, Health Canada, and UK's MHRA between September 2024 and January 2025, expanding treatment access.
Formycon AG has unveiled comprehensive clinical data supporting the comparability of its ustekinumab biosimilar FYB202 to the reference product Stelara® at the European Crohn's and Colitis Organisation (ECCO) Congress in Berlin. The presentation highlights successful outcomes from both phase I and phase III clinical studies, supported by detailed analytical comparability data.
Analytical and Functional Comparability
Advanced laboratory analysis confirmed FYB202's structural and functional similarity to the reference product. The biosimilar demonstrated comparable physicochemical and biological properties, including critical quality attributes such as structure, function, purity, and potency. Functional comparability was specifically verified through IL-12 (搜索) and IL-23 (搜索) binding tests and bioassays, addressing the primary mechanism of action.
Clinical Trial Results
The therapeutic equivalence of FYB202 was established through two key clinical studies:
- A Phase I pharmacokinetics study involving 491 healthy volunteers
- A Phase III efficacy study including 392 patients with moderate to severe plaque psoriasis
These comprehensive results support the extrapolation of FYB202's efficacy to all approved indications of the reference drug, confirming its potential as a safe and effective alternative for patients requiring ustekinumab treatment.
Regulatory Status and Treatment Applications
FYB202, an interleukin inhibitor, received marketing authorization from multiple regulatory bodies:
- European Medicines Agency (EMA) and FDA approval in September 2024
- Health Canada and UK's MHRA approval in January 2025
The biosimilar is indicated for use in both dermatological conditions, specifically psoriasis, and gastroenterological applications for chronic inflammatory bowel disease (搜索) management.
Market Impact and Healthcare Access
The development of FYB202 represents a significant advancement in expanding patient access to critical biological therapies. As part of Formycon's growing biosimilar portfolio, which includes approved products like FYB201 (ranibizumab) and FYB203 (aflibercept), FYB202 contributes to the company's mission of providing cost-effective alternatives to established biologic treatments.
The data presentation at ECCO 2025 (Poster ID: P0879) will take place during the guided poster session on February 21, 2025, offering healthcare professionals detailed insights into the biosimilar's development and clinical performance.